ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Waist-to-Hip Ratio on TRT Predicts Non Calcified Plaque Volume
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 164912" data-attributes="member: 3"><p><strong>Biomarkers and Non-Calcified Coronary Artery Plaque Progression in Older Men Treated with Testosterone</strong></p><p></p><p></p><p>Kashif Shaikh, MD, Susan S Ellenberg, PhD, Rine Nakanishi, MD, PhD, Peter J Snyder, MD, Juhwan Lee, MD,PhD, Nanette K Wenger, MD, Cora E Lewis, MD, Ronald S Swerdloff, MD, Peter Preston, Sajad Hamal, MS </p><p>The Journal of Clinical Endocrinology & Metabolism, dgz242, <a href="https://doi.org/10.1210/clinem/dgz242" target="_blank">https://doi.org/10.1210/clinem/dgz242</a></p><p>Published: 30 November 2019 </p><p></p><p>Abstract</p><p>Objective</p><p>Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) Trials showed that T treatment of older men with low T was associated with greater progression of non-calcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the T Trial.</p><p></p><p>Methods</p><p>The CV part of the trial included 170 men aged 65 years or older with low T. Participants received T gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of CV risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable.</p><p></p><p>RESULTS</p><p>Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio p-0.0014) indicated that this variable impacted the testosterone effect on non-calcified plaque volume. The statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 (95% confidence interval 7.72, 46.20).</p><p></p><p>Conclusion</p><p>Among older men with low T treated for one year, greater waist-hip ratio was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 164912, member: 3"] [B]Biomarkers and Non-Calcified Coronary Artery Plaque Progression in Older Men Treated with Testosterone[/B] Kashif Shaikh, MD, Susan S Ellenberg, PhD, Rine Nakanishi, MD, PhD, Peter J Snyder, MD, Juhwan Lee, MD,PhD, Nanette K Wenger, MD, Cora E Lewis, MD, Ronald S Swerdloff, MD, Peter Preston, Sajad Hamal, MS The Journal of Clinical Endocrinology & Metabolism, dgz242, [URL]https://doi.org/10.1210/clinem/dgz242[/URL] Published: 30 November 2019 Abstract Objective Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) Trials showed that T treatment of older men with low T was associated with greater progression of non-calcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the T Trial. Methods The CV part of the trial included 170 men aged 65 years or older with low T. Participants received T gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of CV risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. RESULTS Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio p-0.0014) indicated that this variable impacted the testosterone effect on non-calcified plaque volume. The statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 (95% confidence interval 7.72, 46.20). Conclusion Among older men with low T treated for one year, greater waist-hip ratio was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Waist-to-Hip Ratio on TRT Predicts Non Calcified Plaque Volume
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top